<p>你可能會認為，<strong>XOMA Royalty Corporation</strong>（NASDAQ:XOMA）以 6.6 倍的市銷率（或稱&#34;P/S&#34;）值得關注，因為幾乎一半的美國生物科技公司市銷率超過 12.1 倍，甚至市銷率高達 93 倍的情況也並不罕見。然而，市銷率低可能是有原因的，需要進一步調查以確定這種情況是否合理。</p>
<p>我們發現 21 只美國股票預計明年將支付超過 6% 的股息收益率。查看完整名單，免費獲取。</p>
<p>查看我們對 XOMA Royalty 的最新分析</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/36769-ps-multiple-vs-industry-1-dark-2/1765825294722?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/36769-ps-multiple-vs-industry-1-dark-2/1765825294722"/></p>
<p>納斯達克 GM:XOMA 市銷率與行業對比 2025 年 12 月 15 日</p>
<h3>XOMA Royalty 的表現如何</h3>
<p>XOMA Royalty 的表現可能更好，因為它的收入增長低於大多數其他公司。也許市場預計當前的收入增長疲軟趨勢將持續，這使得市銷率受到壓制。如果是這樣，現有股東可能會對股價未來的走勢感到失望。</p>
<p>想知道分析師如何看待 XOMA Royalty 的未來與行業的對比嗎？在這種情況下，我們的 <strong>免費</strong> 報告是一個很好的起點。</p>
<h2>XOMA Royalty 是否有收入增長的預測？</h2>
<p>你唯一會真正感到舒適的情況是，當公司的增長預計將落後於行業時，看到像 XOMA Royalty 這樣的低市銷率。</p>
<p>回顧過去一年，公司收入實現了 118% 的顯著增長。最近三年期間，收入整體增長了 16%，這在很大程度上得益於其短期表現。因此，可以公平地説，最近公司的收入增長是相當可觀的。</p>
<p>展望未來，覆蓋該公司的五位分析師的估計顯示，未來三年收入預計每年增長 40%。這明顯低於更廣泛行業預期的 132% 的年增長率。</p>
<p>鑑於此，XOMA Royalty 的市銷率低於大多數其他公司是可以理解的。似乎大多數投資者預計未來增長有限，因此只願意為該股票支付較低的價格。</p>
<h2>最後的總結</h2>
<p>雖然市銷率不應成為你是否購買股票的決定性因素，但它是收入預期的一個相當有效的晴雨表。</p>
<p>我們已經確定，XOMA Royalty 維持其低市銷率是因為其預測增長低於更廣泛行業的預期。在這個階段，投資者認為收入改善的潛力不足以證明更高的市銷率。公司需要運氣的改變才能在未來證明市銷率的上升是合理的。</p>
<p>還值得注意的是，我們發現 <strong>XOMA Royalty 有 2 個警示信號</strong>，你需要考慮。</p>
<p>如果你對盈利的強大公司感興趣，那麼你會想查看這份 <strong>免費</strong> 的有趣公司名單，這些公司以低市盈率交易（但已證明它們能夠增長盈利）。</p>
<p>國防和災難的移動基礎設施</p>
<p>下一波機器人技術不是類人型的。它是完全自主的塔樓，在 30 分鐘內提供 5G、ISR 和雷達，隨時隨地。</p>
<p>在下一輪合同之前獲取投資者簡報</p>
<p>代表 CiTech 贊助</p>

標記臨牀研究

<p>XOMA Royalty Corporation（納斯達克代碼：XOMA）的市銷率（P/S）為 6.6 倍，低於行業平均水平。這是由於其收入增長速度低於更廣泛的生物科技行業。分析師預測，XOMA 在未來三年的年收入增長率為 40%，低於行業 132% 的增長預測。投資者持謹慎態度，預計未來增長有限，因此該股票的市銷率保持在低位。公司需要顯著改善，以證明其更高的市銷率的合理性</p>

<p>You may think that with a price-to-sales (or &#34;P/S&#34;) ratio of 6.6x <strong>XOMA Royalty Corporation</strong> (NASDAQ:XOMA) is a stock worth checking out, seeing as almost half of all the Biotechs companies in the United States have P/S ratios greater than 12.1x and even P/S higher than 93x aren't out of the ordinary. However, the P/S might be low for a reason and it requires further investigation to determine if it's justified.</p>
<div class="lb-trans"><p>你可能會認為，<strong>XOMA Royalty Corporation</strong>（NASDAQ:XOMA）以 6.6 倍的市銷率（或稱&#34;P/S&#34;）值得關注，因為幾乎一半的美國生物科技公司市銷率超過 12.1 倍，甚至市銷率高達 93 倍的情況也並不罕見。然而，市銷率低可能是有原因的，需要進一步調查以確定這種情況是否合理。</p>
</div><p>We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.</p>
<div class="lb-trans"><p>我們發現 21 只美國股票預計明年將支付超過 6% 的股息收益率。查看完整名單，免費獲取。</p>
</div><p>Check out our latest analysis for XOMA Royalty</p>
<div class="lb-trans"><p>查看我們對 XOMA Royalty 的最新分析</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/asset/chart/36769-ps-multiple-vs-industry-1-dark-2/1765825294722" alt="" original-src="https://images.simplywall.st/asset/chart/36769-ps-multiple-vs-industry-1-dark-2/1765825294722"/></p>
<p>NasdaqGM:XOMA Price to Sales Ratio vs Industry December 15th 2025</p>
<div class="lb-trans"><p>納斯達克 GM:XOMA 市銷率與行業對比 2025 年 12 月 15 日</p>
</div><h3>How XOMA Royalty Has Been Performing</h3>
<div class="lb-trans"><h3>XOMA Royalty 的表現如何</h3>
</div><p>XOMA Royalty could be doing better as it's been growing revenue less than most other companies lately. Perhaps the market is expecting the current trend of poor revenue growth to continue, which has kept the P/S suppressed. If this is the case, then existing shareholders will probably struggle to get excited about the future direction of the share price.</p>
<div class="lb-trans"><p>XOMA Royalty 的表現可能更好，因為它的收入增長低於大多數其他公司。也許市場預計當前的收入增長疲軟趨勢將持續，這使得市銷率受到壓制。如果是這樣，現有股東可能會對股價未來的走勢感到失望。</p>
</div><p>Keen to find out how analysts think XOMA Royalty's future stacks up against the industry? In that case, our <strong>free</strong> report is a great place to start.</p>
<div class="lb-trans"><p>想知道分析師如何看待 XOMA Royalty 的未來與行業的對比嗎？在這種情況下，我們的 <strong>免費</strong> 報告是一個很好的起點。</p>
</div><h2>Is There Any Revenue Growth Forecasted For XOMA Royalty?</h2>
<div class="lb-trans"><h2>XOMA Royalty 是否有收入增長的預測？</h2>
</div><p>The only time you'd be truly comfortable seeing a P/S as low as XOMA Royalty's is when the company's growth is on track to lag the industry.</p>
<div class="lb-trans"><p>你唯一會真正感到舒適的情況是，當公司的增長預計將落後於行業時，看到像 XOMA Royalty 這樣的低市銷率。</p>
</div><p>Retrospectively, the last year delivered an exceptional 118% gain to the company's top line. The latest three year period has also seen a 16% overall rise in revenue, aided extensively by its short-term performance. Therefore, it's fair to say the revenue growth recently has been respectable for the company.</p>
<div class="lb-trans"><p>回顧過去一年，公司收入實現了 118% 的顯著增長。最近三年期間，收入整體增長了 16%，這在很大程度上得益於其短期表現。因此，可以公平地説，最近公司的收入增長是相當可觀的。</p>
</div><p>Shifting to the future, estimates from the five analysts covering the company suggest revenue should grow by 40% per annum over the next three years. That's shaping up to be materially lower than the 132% per year growth forecast for the broader industry.</p>
<div class="lb-trans"><p>展望未來，覆蓋該公司的五位分析師的估計顯示，未來三年收入預計每年增長 40%。這明顯低於更廣泛行業預期的 132% 的年增長率。</p>
</div><p>In light of this, it's understandable that XOMA Royalty's P/S sits below the majority of other companies. It seems most investors are expecting to see limited future growth and are only willing to pay a reduced amount for the stock.</p>
<div class="lb-trans"><p>鑑於此，XOMA Royalty 的市銷率低於大多數其他公司是可以理解的。似乎大多數投資者預計未來增長有限，因此只願意為該股票支付較低的價格。</p>
</div><h2>The Final Word</h2>
<div class="lb-trans"><h2>最後的總結</h2>
</div><p>While the price-to-sales ratio shouldn't be the defining factor in whether you buy a stock or not, it's quite a capable barometer of revenue expectations.</p>
<div class="lb-trans"><p>雖然市銷率不應成為你是否購買股票的決定性因素，但它是收入預期的一個相當有效的晴雨表。</p>
</div><p>We've established that XOMA Royalty maintains its low P/S on the weakness of its forecast growth being lower than the wider industry, as expected. At this stage investors feel the potential for an improvement in revenue isn't great enough to justify a higher P/S ratio. The company will need a change of fortune to justify the P/S rising higher in the future.</p>
<div class="lb-trans"><p>我們已經確定，XOMA Royalty 維持其低市銷率是因為其預測增長低於更廣泛行業的預期。在這個階段，投資者認為收入改善的潛力不足以證明更高的市銷率。公司需要運氣的改變才能在未來證明市銷率的上升是合理的。</p>
</div><p>It is also worth noting that we have found <strong>2 warning signs for XOMA Royalty</strong> that you need to take into consideration.</p>
<div class="lb-trans"><p>還值得注意的是，我們發現 <strong>XOMA Royalty 有 2 個警示信號</strong>，你需要考慮。</p>
</div><p>If strong companies turning a profit tickle your fancy, then you'll want to check out this <strong>free</strong> list of interesting companies that trade on a low P/E (but have proven they can grow earnings).</p>
<div class="lb-trans"><p>如果你對盈利的強大公司感興趣，那麼你會想查看這份 <strong>免費</strong> 的有趣公司名單，這些公司以低市盈率交易（但已證明它們能夠增長盈利）。</p>
</div><p>Mobile Infrastructure for Defense and Disaster</p>
<div class="lb-trans"><p>國防和災難的移動基礎設施</p>
</div><p>The next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.</p>
<div class="lb-trans"><p>下一波機器人技術不是類人型的。它是完全自主的塔樓，在 30 分鐘內提供 5G、ISR 和雷達，隨時隨地。</p>
</div><p>Get the investor briefing before the next round of contracts</p>
<div class="lb-trans"><p>在下一輪合同之前獲取投資者簡報</p>
</div><p>Sponsored On Behalf of CiTech</p>
<div class="lb-trans"><p>代表 CiTech 贊助</p>
</div>

投資者看不到標記臨牀研究公司（納斯達克股票代碼：XOMA）隧道盡頭的曙光